Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events

Bliden, Kevin P.; Tantry, Udaya S.; Chaudhary, Rahul; Byun, Seunghwan; Gurbel, Paul A.

doi:10.1080/14779072.2016.1188005

Cited by 3 publications

(2 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since these medications have previously come through the requisite validation processes for their usage, the time required for their approval in other conditions is reduced. The most common cause of this situation is given by acetylsalicylic acid, which was approved as an analgesic and years later as a vascular protector [33]. Tree-repurposed drugs were approved by WHO for the treatment of tuberculosis: linezolid, used in nosocomial pneumonia, clofazimine (an antileprosy drug), and meropenem, a β-lactam antibiotic [34].…”

Section: Alternative Treatments and Their Availabilitymentioning

confidence: 99%

New Alternatives in the Fight against Tuberculosis: Possible Targets for Resistant Mycobacteria

Rodríguez-Bustamante,

Gómez-Manzo,

De Obeso Fernández del Valle

et al. 2023

Processes

View full text Add to dashboard Cite

Tuberculosis (TB) is a bacterial disease that remains a global health threat due to the millions of deaths attributed to it each year. The emergence of drug resistance has exacerbated and further increased the challenges in the fight against this illness. Despite the preventive measures using the application of the Bacillus Calmette-Guérin vaccine, the desired immunization outcome is not as high as expected. Conventional TB treatments exhibit serious limitations, such as adverse effects and prolonged duration, leading to a pressing need for alternative and more effective treatment options. Despite significant efforts, it took nearly four decades for diarylquinoline to become the most recently approved medicine for this disease. In addition, various possibilities, such as the usage of medications used for many other conditions (repurposed drugs), have been explored in order to speed up the process of achieving faster outcomes. Natural compounds derived from various sources (microorganisms, plants, and animals) have emerged as potential candidates for combating TB due to their chemical diversity and their unique modes of action. Finally, efforts towards the generation of novel vaccines have received considerable attention. The goal of this paper was to perform an analysis of the current state of treating drug-resistant TB and to evaluate possible approaches to this complicated challenge. Our focus is centered on highlighting new alternatives that can be used to combat resistant strains, which have potentiated the health crisis that TB represents.

show abstract

Section: Alternative Treatments and Their Availabilitymentioning

confidence: 99%

New Alternatives in the Fight against Tuberculosis: Possible Targets for Resistant Mycobacteria

Rodríguez-Bustamante,

Gómez-Manzo,

De Obeso Fernández del Valle

et al. 2023

Processes

View full text Add to dashboard Cite

show abstract

“…An extended-release formulation of aspirin developed to address some of these limitations recently came out. This may be an alternative to standard aspirin in the secondary prevention of cardiovascular disease because of the decreased bleeding risk of the therapy in conjunction with potent P2Y12 receptor blockers and/or oral anticoagulants [ 58 ].…”

Section: Thromboxane and Strokementioning

confidence: 99%

The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review

Kozioł

Kotlęga

Brodowski

et al. 2021

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases are currently among the leading causes of morbidity and mortality in many developed countries. They are distinguished by chronic and latent development, a course with stages of worsening of symptoms and a period of improvement, and a constant potential threat to life. One of the most important disorders in cardiovascular disease is ischemic stroke. The causes of ischemic stroke can be divided into non-modifiable and modifiable causes. One treatment modality from a neurological point of view is acetylsalicylic acid (ASA), which blocks cyclooxygenase and, thus, thromboxane synthesis. The legitimacy of its administration does not raise any doubts in the case of the acute phase of stroke in patients in whom thrombolytic treatment cannot be initiated. The measurement of thromboxane B2 (TxB2) in serum (a stable metabolic product of TxA2) is the only test that measures the effect of aspirin on the activity of COX-1 in platelets. Measurement of thromboxane B2 may be a potential biomarker of vascular disease risk in patients treated with aspirin. The aim of this study is to present the role of thromboxane B2 in ischemic stroke and to present effective therapies for the treatment of ischemic stroke. Scientific articles from the PubMed database were used for the work, which were selected on the basis of a search for “thromboxane and stroke”. Subsequently, a restriction was introduced for works older than 10 years, those concerning animals, and those without full text access. Ultimately, 58 articles were selected. It was shown that a high concentration of TXB2 may be a risk factor for ischemic stroke or ischemic heart disease. However, there is insufficient evidence to suggest that thromboxane could be used in clinical practice as a marker of ischemic stroke. The inclusion of ASA in the prevention of stroke has a beneficial effect that is associated with the effect on thromboxane. However, its insufficient power in 25% or even 50% of the population should be taken into account. An alternative and/or additional therapy could be a selective antagonist of the thromboxane receptor. Thromboxane A2 production is inhibited by estrogen; therefore, the risk of CVD after the menopause and among men is higher. More research is needed in this area.

show abstract

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

et al. 2018

View full text Add to dashboard Cite

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly known as aspirin) has been the mainstay of treatment for decades owing to its capacity to reduce the risk of ischaemic events. Accordingly, novel antithrombotic therapies have been traditionally tested on a background of acetylsalicylic acid therapy. Although the adjunctive use of such antithrombotic therapies can potentially further reduce the risk of ischaemic events, these agents are also inevitably associated with an increased risk of bleeding. However, acetylsalicylic acid also increases the risk of bleeding, challenging the paradigm that this agent should remain the cornerstone of antiplatelet treatment when alternative antithrombotic agents are also used. Many antithrombotic compounds are characterized by increased potency and consistent efficacy, which might lessen the need for concomitant acetylsalicylic acid. Accordingly, numerous investigations are testing the hypothesis that acetylsalicylic acid-sparing regimens based on newer antithrombotic agents might have an increased net benefit for individual patients owing to the reduction in bleeding risk, without a trade-off in efficacy. This Review summarizes the state of the art relating to antithrombotic approaches with and without acetylsalicylic acid for the prevention of cardiovascular disease and cardioembolic stroke. Discussion of the scientific rationale, from bench to bedside, for ongoing studies of acetylsalicylic acid-free pharmacological strategies is included.

show abstract

Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events

Cited by 3 publications

References 71 publications

New Alternatives in the Fight against Tuberculosis: Possible Targets for Resistant Mycobacteria

New Alternatives in the Fight against Tuberculosis: Possible Targets for Resistant Mycobacteria

The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

Contact Info

Product

Resources

About